Novartis Investigative Site

Nepean, Ontario K2G 6E2

0 studies enrolling now · 3 studies all time

What they study most

Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis

Studies at this site

• Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis — Completed
• A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis — Completed
• Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program — Completed